Select Page

Tigermed Insights

Home » Insights

At Tigermed, we believe knowledge needs to be shared to further develop clinical programs, increase market access, and to meet unmet patients needs. This is why we share publications, blogs and other insights here.

Hear from thought leaders and other subject matter experts on the topics, trends and market developments that are relevant to clinical trials and related areas. Remember that you are always invited to request additional information or suggest a topic you would like to learn more about. Use the contact page to reach us for any requests.

Orphan Drug Development in China

Orphan Drug Development in China

In this blog post, we will shortly outline the regulatory framework for orphan drug development in the USA and Europe, and then focus on recent developments and future prospects in China.

What’s New for the MAH in China?

What’s New for the MAH in China?

After the pilot program in ten provinces and municipal cities for 3 years, the MAH system becomes one of the twelve chapters of the revised Drug Administration Law, which was put into effect since De 1, 2019.

What’s New for Clinical Trials in China?

What’s New for Clinical Trials in China?

On March 30, 2020, the revised Drug Registration Regulation (DRR) was issued by the State Administration for Marketing Regulation and will be put into effect from July 1, 2020